# Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

> **NCT04131543** · PHASE2 · UNKNOWN · sponsor: **University of Bologna** · enrollment: 25 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Cabozantinib 20 MG
- **DRUG:** Cabozantinib 40 MG
- **DRUG:** Cabozantinib 60 MG

## Key facts

- **NCT ID:** NCT04131543
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-07
- **Primary completion:** 2020-08-07
- **Final completion:** 2022-08-07
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-10-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131543, "Phase II Study With Cabozantinib in Patients With RET Positive NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04131543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*